Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

The global respiratory inhaler devices market is on the cusp of significant transformation over the next decade, driven by a rising incidence of respiratory diseases, technological advancements, and ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...

Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Dupixent for the treatment of COPD has been approved in more than ... About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy. Patients with COPD and ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. ProAir HFA Inhalers provides respiratory relief of bronchospasm and wheezing through ...

Despite the promising market growth, regulatory compliance and stringent guidelines continue to pose challenges for MDI manufacturers. Regulatory bodies worldwide are tightening restrictions on ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease ...